Management of Uterine Fibroids

Introduction to Management Options

The American College of Radiology recommends treatment selection for symptomatic uterine fibroids based on fertility desires, symptom type, and fibroid characteristics, with first-line medical management using hormonal contraceptives or NSAIDs for bleeding control, progressing to GnRH antagonists with add-back therapy for inadequate response, and reserving surgical options for when medical management fails 1, 2, 3

The American College of Radiology suggests starting with estrogen-progestin oral contraceptive pills or levonorgestrel-releasing IUD as first-line options for heavy menstrual bleeding, as these effectively reduce bleeding symptoms with the strongest evidence base 1, 3, 5
NSAIDs provide direct pain control and modest reduction in menstrual blood loss, making them appropriate for patients with both bleeding and pain 3, 5
Tranexamic acid is the preferred nonhormonal alternative for patients who cannot or will not use hormonal options, with significant reduction in menstrual blood loss 2, 3
Oral GnRH antagonists with hormone add-back therapy are the most effective second-line agents, significantly reducing both bleeding and fibroid volume 2, 3, 4

For patients desiring fertility preservation, hysteroscopic myomectomy is the procedure of choice for submucosal fibroids <5 cm, offering shorter hospitalization and faster recovery than other surgical approaches 1, 2
Laparoscopic or open myomectomy is indicated for intramural or subserosal fibroids causing symptoms or cavity distortion 1, 4
Preoperative imaging of the uterine cavity is mandatory before attempting conception, as UPA treatment can induce fibroid migration and cavity changes 6

Uterine Artery Embolization (UAE) is an effective alternative to myomectomy and hysterectomy for symptomatic fibroids in patients not desiring pregnancy, with average fibroid size decrease >50% at 5 years 1, 4
MR-Guided Focused Ultrasound (MRgFUS) uses high-intensity ultrasound waves to thermally ablate fibroids with significant improvement in quality of life and 18% decrease in fibroid diameter compared to placebo 4

For anemic patients, correct anemia with iron supplementation while simultaneously initiating GnRH agonists or antagonists to control bleeding and reduce fibroid size 6, 4
Short courses of GnRH therapy effectively shrink fibroids and may facilitate minimally invasive surgical approaches 2, 3

Hysteroscopic myomectomy is the definitive procedure of choice for pedunculated submucosal fibroids <5 cm 2
Suspect fibroid degeneration if patient presents with severe sudden-onset pain, fever, nausea, and leukocytosis, and provide supportive care with NSAIDs and observation 5

Never use long-term GnRH agonists or antagonists without add-back therapy, as this leads to significant bone mineral density loss 3, 5
Most medical treatments provide only temporary symptom relief with rapid recurrence after discontinuation, requiring ongoing management or eventual surgical intervention 3, 5
Hysterectomy has been associated with increased long-term risks of cardiovascular disease, osteoporosis, bone fracture, and dementia in cohort studies 5